60965-25-5

Basic information

• Product Name: Ethanone, 1-(5-bromo-2,4-dihydroxyphenyl)-
• Synonyms: 1-(5-bromo-2,4-dihydroxy-phenyl)-ethanone;Ethanone,1-(5-bromo-2,4-dihydroxyphenyl);5-bromo-2,4-dihydroxyacetophenone;5'-Brom-2',4'-dihydroxy-acetophenon;bromoresacetophenone;1-(5-Brom-2,4-dihydroxy-phenyl)-aethanon
• CAS NO: 60965-25-5
• Molecular Formula: C8H7BrO3
• Molecular Weight: 231.046
• Mol File: 60965-25-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 171°C
• CAS DataBase Reference: Ethanone, 1-(5-bromo-2,4-dihydroxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(5-bromo-2,4-dihydroxyphenyl)-(60965-25-5)
• EPA Substance Registry System: Ethanone, 1-(5-bromo-2,4-dihydroxyphenyl)-(60965-25-5)

Safety Data

• Hazardous Substances Data: 60965-25-5(Hazardous Substances Data)

Usage

Preparation

Preparation by reaction of acetic acid on 4-bromoresorcinol with zinc chloride (Nencki reaction).

Upstream product

• 6626-15-9 4-Bromoresorcinol 
• 64-19-7 acetic acid 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 42059-48-3 acetic acid 4-acetyl-3-hydroxyphenyl ester 

Downstream Products

• 78050-54-1 (E)-1-(5-Bromo-2,4-dihydroxy-phenyl)-3-(3-hydroxy-4-methoxy-phenyl)-propenone 
• 145489-48-1 5-bromo-2-hydroxy-3-iodo-4-phenoxyacetophenone 
• 850398-70-8 1-(3-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-72-0 1-(5-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-71-9 1-(3,5-bis-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 1313728-38-9 1-[5-bromo-2-hydroxy-4-(methoxymethoxy)phenyl]ethenone 
• 1313728-65-2 (Z)-3-(7-benzyloxy-4-oxo-4H-1-benzopyran-6-yl)acrylonitrile 
• 1313728-64-1 (E)-3-(7-benzyloxy-4-oxo-4H-1-benzopyran-6-yl)acrylonitrile 
• 1313728-62-9 (E)-3-(7-benzyloxy-4-oxo-4H-1-benzopyran-6-yl)-2-propenal 
• 1313728-63-0 ethyl 3-(7-benzyloxy-4-oxo-4H-1-benzopyran-6-yl)propanoate 
• 1313728-59-4 ethyl (E)-3-(7-benzyloxy-4-oxo-4H-1-benzopyran-6-yl)acrylate 
• 1313728-56-1 (E)-7-benzyloxy-6-styrylchromone 
• 1313728-55-0 (E)-7-methoxymethoxy-6-styrylchromone 
• 1313728-51-6 7-benzyloxy-6-bromo-2-hydroxychroman-4-one 

Relevant articles and documents

o-xylylene bis(triethyl ammonium tribromide) as a mild and recyclable reagent for rapid and regioselective bromination of anilines and phenols

Background: o-Xylylene bis(triethyl ammonium tribromide) (OXBTEATB) as a recyclable and high bromine containing di-(tribromide) reagent has been employed for the bromination of various organic substrates such as phenol and aniline or its derivatives. This catalyst can be recovered and reused several times. Methods: Aryl bromides shown in Table 1, were easily produced from bromination of aromatic compounds by OXBTEATB. This high-yield process lets the reagents to be recycled and reused. Results: As shown in Table 1, substituted anilines, phenols and β-naphthol were found to be the most reactive and immediately converted to the corresponding mono-brominated products by OXBTEATB. Conclusion: OXBTEATB can be considered a solidified bromine. This novel reagent has variable solubility in different polar protic and aprotic solvents but insoluble in non-polar aprotic solvent. Subsequently, OXBTEATB can be recognized as a more useful brominating and regioselective catalyst than the liquid bromine.

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.